Edition:
United Kingdom

Aralez Pharmaceuticals Inc (ARLZ.OQ)

ARLZ.OQ on NASDAQ Stock Exchange Global Select Market

1.37USD
24 Apr 2018
Change (% chg)

$0.04 (+3.01%)
Prev Close
$1.33
Open
$1.33
Day's High
$1.40
Day's Low
$1.33
Volume
36,267
Avg. Vol
99,787
52-wk High
$2.98
52-wk Low
$0.95

Latest Key Developments (Source: Significant Developments)

Aralez Pharmaceuticals Says Unit Entered Into Modification Of Contract
Thursday, 5 Apr 2018 

April 5 (Reuters) - Aralez Pharmaceuticals Inc ::ARALEZ PHARMA - UNIT ENTERED INTO MODIFICATION OF CONTRACT PURSUANT TO WHICH U.S. EXERCISED SECOND RENEWAL OPTION UNDER THAT VA NATIONAL CONTRACT.ARALEZ PHARMA SAYS CONTRACT MODIFICATION EXTENDS TERM OF AGREEMENT TO APRIL 28, 2019 - SEC FILING.ARALEZ PHARMA - MODIFICATION INCLUDES SAME PRICING TERMS DURING APRIL 29, 2017 THROUGH APRIL 28 ANNUAL TERM EXCEPT FOR PRICE DECREASE TO 200MG SKUS.  Full Article

Aralez Pharmaceuticals Inc - ‍On March 13, Board Appointed Michael Kaseta As Company's CFO - SEC Filing
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Aralez Pharmaceuticals Inc ::ARALEZ PHARMACEUTICALS INC - ‍ON MARCH 13, BOARD APPOINTED MICHAEL KASETA AS COMPANY'S CFO - SEC FILING.  Full Article

Aralez Announces Departure Of Chief Financial Officer
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Aralez Pharmaceuticals Inc ::ARALEZ ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER.ARALEZ PHARMACEUTICALS INC - ‍SCOTT J. CHARLES, CHIEF FINANCIAL OFFICER, IS LEAVING COMPANY​.ARALEZ PHARMACEUTICALS INC - MICHAEL KASETA WILL ASSUME POSITION OF INTERIM CHIEF FINANCIAL OFFICER.ARALEZ PHARMACEUTICALS INC - ‍ PRIOR TO JOINING ARALEZ, KASETA SERVED AS CFO OF SANOFI NORTH AMERICA, GLOBAL SERVICES​.  Full Article

Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Lannett Company Inc ::LANNETT ANNOUNCES AGREEMENT FOR AUTHORIZED GENERIC VERSION OF TOPROL-XL®.LANNETT COMPANY INC - FINANCIAL TERMS WERE NOT DISCLOSED..LANNETT COMPANY INC - HAS ENTERED INTO AN AGREEMENT WITH ARALEZ PHARMACEUTICALS TRADING DAC.LANNETT COMPANY - ‍AGREEMENT WITH ARALEZ PHARMACEUTICALS TRADING DAC TO BECOME EXCLUSIVE DISTRIBUTOR IN U.S. OF AUTHORIZED GENERIC VERSION OF TOPROL-XL​.LANNETT COMPANY INC - DEAL TO BECOME EXCLUSIVE DISTRIBUTOR IN U.S. OF TOPROL-XL EXTENDED RELEASE TABLETS IN 25 MG, 50 MG, 100 MG AND 200MG.  Full Article

Aralez Pharmaceuticals files for mixed shelf offering of up to $100 mln - SEC filing‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Aralez Pharmaceuticals Inc :Aralez Pharmaceuticals Inc - files for mixed shelf offering of up to $100 million - SEC filing‍​.  Full Article

Aralez sees 2018 net revenues $140 mln to $160 mln‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Aralez Pharmaceuticals Inc :Aralez announces third quarter 2017 financial results and achieves profitability on an adjusted EBITDA basis for the first time in the third quarter.Aralez Pharmaceuticals Inc - ‍provides updated 2017 full-year guidance and preliminary 2018 full-year outlook​.Aralez Pharmaceuticals Inc - ‍plans to implement further financial improvements designed to streamline U.S. business​.Aralez Pharmaceuticals Inc - ‍net loss in Q3 of 2017 was $24.4 million, or $0.37 per diluted share​.Qtrly total revenues, net $24.3 million versus $13.6 mln‍​.Aralez Pharmaceuticals Inc - ‍updated 2017 net revenues to be in a range of $95 million to $105 million​.Aralez Pharmaceuticals Inc - sees 2018 net revenues $140 million to $160 million‍​.  Full Article

Aralez Q2 GAAP loss per share $0.27
Tuesday, 9 Aug 2016 

Aralez Pharmaceuticals Inc : Aralez reports second quarter 2016 financial results . Q2 revenue $12.6 million versus $5.2 million . Q2 GAAP loss per share $0.27 .Q2 earnings per share view $-0.22, revenue view $11.9 million -- Thomson Reuters I/B/E/S.  Full Article

Aralez posts Q1 loss of $0.73/share
Tuesday, 10 May 2016 

Aralez Pharmaceuticals Inc : Aralez reports first quarter 2016 financial results . Qtrly GAAP loss per share $0.73 .Total net revenues for three months ended March 31, 2016 were about $8.1 million compared to $4.4 million.  Full Article

BRIEF-Aralez Pharmaceuticals Says Unit Entered Into Modification Of Contract

* ARALEZ PHARMA - UNIT ENTERED INTO MODIFICATION OF CONTRACT PURSUANT TO WHICH U.S. EXERCISED SECOND RENEWAL OPTION UNDER THAT VA NATIONAL CONTRACT